Ki H. Lee, MD

Overview

Ki Hyeong Lee, MD, MS, is a board-certified neurologist and epileptologist with AdventHealth Medical Group and the Medical Director of AdventHealth for Children’s pediatric epilepsy center in Orlando. A leading provider of diagnostic and surgical techniques for addressing epilepsy and seizures, Dr. Lee completed three prestigious fellowships in clinical neurophysiology, epilepsy research and stroke at the Medical College of Georgia, Mayo Clinic Foundation in Minneapolis and Seoul National University Hospital in Korea, respectively. A noted researcher who regularly presents his work in published articles and international medical forums, he constantly seeks to advance the state of epilepsy patient care through medical breakthroughs and new technologies.

Articles

Palliation for catastrophic nonlocalizing epilepsy: a retrospective case series of complete corpus callosotomy at a single institution

JOURNAL OF NEUROSURGERY-PEDIATRICS

2023

Intracranial EEG and laser interstitial thermal therapy in MRI-negative insular and/or cingulate epilepsy: case series

JOURNAL OF NEUROSURGERY

2021

Deep Learning Provides Exceptional Accuracy to ECoG-Based Functional Language Mapping for Epilepsy Surgery

FRONTIERS IN NEUROSCIENCE

2020

Altered integrity of corpus callosum in generalized epilepsy in relation to seizure lateralization after corpus callosotomy

NEUROSURGICAL FOCUS

2020

Anakinra usage in febrile infection related epilepsy syndrome: an international cohort

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY

2020

Autoimmune encephalitis and epilepsy: evolving definition and clinical spectrum

Clinical and experimental pediatrics

2020

Epilepsy Surgery in Children versus Adults

JOURNAL OF KOREAN NEUROSURGICAL SOCIETY

2019

Usefulness of intraoperative insular electrocorticography in modified functional hemispherectomy

BMC NEUROLOGY

2017

Impact of intraoperative 3-T MRI with diffusion tensor imaging on hemispherectomy

JOURNAL OF NEUROSURGERY-PEDIATRICS

2017

The role of executive functioning in quality of life in pediatric intractable epilepsy

EPILEPSY & BEHAVIOR

2016

Associated Clinical Trials

NCT06132893

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of the BHV7000 in Subjects with Refractory Focal Onset Epilepsy

$Icon for trial | BHV7000-302-021 A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of the BHV7000 in Subjects with Refractory Focal Onset Epilepsy$

This study is currently enrolling.

This is a research study to test a new investigational drug. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA). The main purpose of this study is to assess whether an in ...

NCT05626634

A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous treatment for up to 52 weeks.

You, or you and the individual you care for, are being asked to take part in a research study because you have seizures associated with developmental and epileptic encephalopathy (DEE) and you have completed study LP352-201. L ...

NCT05064878

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Fixed-Dose, Multicenter Study to Examine the Efficacy and Safety of ZX008 in Subjects with CDKL5 deficiency disorder followed by an Open-Label Extension.

The purpose of this informed consent form is to collect data about the non-paid caregiver of a subject that is participating in ZX008-2103 study. You, as the non-paid caregiver, are being asked to complete the EQ-5D-5L Quality ...

NCT05076838

An Open-Label, Single-Dose, Pharmacokinetics Study of VALTOCO with Open-Label Safety Period in Pediatric Subjects with Epilepsy

This is a research study to evaluate the pharmacokinetics (PK), safety and tolerability after a single intranasal dose of VALTOCO (diazepam nasal spray), followed by a long-term safety period, where VALTOCO will be used “as nee ...

Ki H. Lee , MD

Overview

Articles

Palliation for catastrophic nonlocalizing epilepsy: a retrospective case series of complete corpus callosotomy at a single institution

Intracranial EEG and laser interstitial thermal therapy in MRI-negative insular and/or cingulate epilepsy: case series

Deep Learning Provides Exceptional Accuracy to ECoG-Based Functional Language Mapping for Epilepsy Surgery

Altered integrity of corpus callosum in generalized epilepsy in relation to seizure lateralization after corpus callosotomy

Anakinra usage in febrile infection related epilepsy syndrome: an international cohort

Autoimmune encephalitis and epilepsy: evolving definition and clinical spectrum

Epilepsy Surgery in Children versus Adults

Usefulness of intraoperative insular electrocorticography in modified functional hemispherectomy

Impact of intraoperative 3-T MRI with diffusion tensor imaging on hemispherectomy

The role of executive functioning in quality of life in pediatric intractable epilepsy

Education & Training

Education

Fellowship

Specialty

Board Certifications

Associated Clinical Trials

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of the BHV7000 in Subjects with Refractory Focal Onset Epilepsy

A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous treatment for up to 52 weeks.

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Fixed-Dose, Multicenter Study to Examine the Efficacy and Safety of ZX008 in Subjects with CDKL5 deficiency disorder followed by an Open-Label Extension.

An Open-Label, Single-Dose, Pharmacokinetics Study of VALTOCO with Open-Label Safety Period in Pediatric Subjects with Epilepsy

Explore

Institutes